Modis Therapeutics, a Columbia University spinout focused on a rare mitochondrial disease, has been bought by Zogenix in a deal potentially worth $400m.

SoftBank-backed genome medical research tech provider 10x Genomics, previously backed by SoftBank, filed to go public. This may be a notable exit in burgeoning genomics and gene technology space, which has seen much corporate backing in recent years.

Microbiome drug developer Finch Therapeutics has collected investments from SymBiosis and SIG among others to push its total funding to near $95m.

Existing investors Celgene and Astellas returned to back the virus-based cancer therapy developer's $79.5m series B round to take its total funding to more than $140m.

Kaiser Permanente Ventures and Providence Ventures were among the investors that helped health data management platform Protenus take its overall funding above $35m.

SoftBank-backed medical research technology provider 10x Genomics, valued at nearly $1.3bn as of this year, has filed to go public.

Anti-cancer antibody developer IGM has filed to raise up to $100m, weeks after securing $102m in a Haldor Topsøe-backed series C round.

Osage University Partners-backed Satsuma has filed for an $86.3m initial public offering that will fund phase 3 trials of its migraine candidate.

The university spun out 19 businesses over the course of 2018-19, including orthodontic device producer Invisia and dietary insights software developer Eaterpad.